Neuroprotective effects of MTEP, a selective mGluR5 antagonist and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures

Pharmacological Reports

Volumn 58, Issue 6, 2006, Pages 846-858

  Domin, Helena ^a   Kajta, Małgorzata ^a   Śmiałowska, Maria ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Excitotoxicity; Kainic acid; MGluRs; MTEP; Neuroprotection; NPY; Primary neuronal cultures

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; CASPASE 3; KAINIC ACID; LACTATE DEHYDROGENASE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; NEUROPEPTIDE Y;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME RELEASE; EXCITOTOXICITY; HIPPOCAMPUS; MOUSE; NEOCORTEX; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION;

EID: 33846306749     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Akins PT, Atkinson RP: Glutamate AMPA receptor antagonist treatment for ischaemic stroke. Curr Med Res Opin, 2002, 18, 9-13.
2. Alexander GM, Godwin DW: Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res, 2006, 71, 1-22.
3. Allen JW, Knoblach SM, Faden AI: Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ, 2000, 7, 470-476.
4. Allen JW, Vicini S, Faden AI: Exacerbation of neuronal cell death by activation of group I metabotropic glutamate receptors: role of NMDA receptors and arachidonic acid release. Exp Neurol, 2001, 169, 449-460.
5. Anderson JJ, Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Roppe J, King C et al.: In vivo receptor occupancy of mGluR5 receptor antagonists using the novel radioligand [3H] 3-methoxy-5-(pyridin-2-ytethynyl) pyridine). Eur J Pharmacol, 2003, 473, 35-40.
6. Anderson JJ, Rao SP, Rowe B, Giracello DR, Holtz G, Chapman DF, Tehrani L et al.: [3H]Methoxymethyl-3-[(2-methyl-1, 3-thiazol-4-yl) ethynyl] pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther, 2002, 303, 1044-1051.
7. Bao WL, Williams AJ, Faden AI, Tortella FC: Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res, 2001, 922, 173-179.
8. Bijak M, Śmiałowska M: Effects of neuropeptide Y evoked potentials in the CA1 region and the dentate gyrus of the rat hippocampal slice. Pol J Pharmacol, 1995, 47, 333-338.
9. Brewer GJ: Serum-free B27/neurobasal medium supports differentiated growth of neurones from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J Neurosci Res, 1995, 42, 674-683.
10. Bruno V, Copani A, Battaglia G, Rafaele R, Shinozaki H, Nicoletti F: Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. Eur J Pharmacol, 1994, 256, 109-112.
11. Bruno V, Copani A, Knopfel T, Kuhn R, Casabona G, Dell'Albani P, Condorello DF, Nicoletti F: Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology, 1995, 34, 1089-1098.
12. Bruno V, Copani A, Bonanno L, Knoepfel T, Kuhn R, Roberts PJ, Nicoletti F: Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur J Pharmacol, 1996, 310, 61-66.
13. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, Knopfel T, Kuhn R, Nicoletti F: The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci, 1997, 17, 1891-1897.
14. Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F: Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology, 1999, 38, 199-207.
15. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, Gasparini F et al.: Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 2000, 39, 2223-2230.
16. Canzoniero LMT, Babcock DJ, Gottron FJ, Grabb MC, Manzerra P, Snider BJ, Choi DW: Raising intracellular calcium attenuates neuronal apoptosis triggered by staurosporine or oxygen-glucose deprivation in the presence of glutamate receptor blockade. Neurobiol Dis, 2004, 15, 520-528.
17. Choi DW: Excitotoxic cell death. J Neurobiol, 1992, 23, 1267-1276.
18. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1988, 1, 623-634.
19. Choi DW: Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett, 1985, 58, 293-297.
20. Choi DW: Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res, 1994, 100, 47-51.
21. Colmers WF: Modulation of synaptic transmission in hippocampus by neuropeptide Y: presynaptic actions. Ann NY Acad Sci, 1990, 611, 206-218.
22. 2 receptor. Br J Pharmacol, 1991, 102, 41-44.
23. Colmers WF, Lukowiak K, Pittman QJ: Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J Physiol, 1987, 383, 285-299.
24. Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, Rao S, Varney MA: [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett, 2003, 13, 351-354.
25. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L et al.: 3-[(2-Methyl-1, 3-thiazol-4-yl)-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem, 2003, 46, 204-206.
26. Coyle JT: Neurotoxic action of kainic acid. J Neurochem, 1993, 41, 1-11.
27. Danysz W, Parsons CG: Glycine and N-methyl-D-asparate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev, 1998, 50, 597-664.
28. Davies CH, Clarke VRJ, Jane DE, Collingridge GL: Pharmacology of postsynaptic metabotropic glutamate receptors in rat hippocampal CA1 pyramidal neurones. Br J Pharmacol, 1995, 116, 1859-1869.
29. Djebaili M, De Bock F, Baille V, Bockaert J, Rondouin G: Implication of p53 and caspase-3 in kainic acid but not in N-methyl-D-aspartic acid-induced apoptosis in organotypic hippocampal mouse cultures. Neurosci Lett, 2002, 327, 1-4.
30. Dumont Y, Martel JC, Fournier A, St Pierre S, Quirion R: Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol, 1992, 38, 125-167.
31. Faden AI, O'Leary DM, Fan L, Bao W, Mullins PGM, Movsesyan VA: Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma. Exp Neurol, 2001, 167, 435-444.
32. Fazal A, Parker F, Palmer AM, Croucher MJ: Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium-dependent re-uptake in rat cerebrocortical minislices. J Neurochem, 2003, 86, 1346-1358.
33. Ferkany JW, Coyle JT: Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids. J Pharmacol Exp Ther, 1983, 225, 399-406.
34. Filipkowski R, Hetman M, Kamińska B, Kaczmarek L: DNA fragmentation in rat brain after intraperitoneal administration of kainate. Neuroreport, 1994, 5, 1538-1540.
35. Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V: Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol, 2002, 513, 197-223.
36. Garthwaite G, Garthwaite J: Neurotoxicity of excitatory amino acid receptor agonists in rat cerebellar slices: dependence on calcium concentration. Neurosci Lett, 1986, 66, 193-198.
37. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D et al.: (R, S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther, 1999, 289, 1678-1687.
38. Gereau RW and Conn PJ: Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. J Neurophysiol, 1995, 74, 122-129.
39. Gray TS, Morley JE: Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. Life Sci, 1986, 38, 389-401.
40. Greber S, Schwarzer C, Sperk G: Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br J Pharmacol, 1994, 113, 737-740.
41. Hunter AJ, Green AR, Cross AJ: Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? TiPS, 1995, 16, 123-128.
42. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol, 2002, 1, 383-386.
43. Kajta M, Budziszewska B, Lasoń W: Allopregnanolone attenuates kainate-induced toxicity in primary cortical neurons and PC12 neuronal cells. Pol J Pharmacol, 1999, 51, 531-534.
44. Kajta M: Apoptosis in the central nervous system: mechanisms and protective strategies. Pol J Pharmacol, 2004, 6, 659-700.
45. Kajta M, Lasoń W: Oestrogen effects on kainate-induced toxicity in primary cultures of rat cortical neurons. Acta Neurobiol Exp, 2000, 60, 365-369.
46. Kajta M, Lasoń W, Kupiec T: Effects of estrone on N-methyl-D-aspartic acid- and staurosporine-induced changes in caspase-3-like protease activity and lactate dehydrogenase-release: time and tissue-dependent effects in neuronal cultures. Neuroscience, 2004, 123, 515-526.
47. Kajta, M, Trotter A, Lasoń W, Beyer C: Effect of NMDA on staurosporine-induced activation of caspase-3 and LDH release in mouse neocortical and hippocampal cells. Brain Res Dev Brain Res, 2005, 160, 40-52.
48. 2 production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res, 2001, 908, 1-9.
49. Klapstein GJ, Colmers WF: On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus, 1993, 3, 103-112.
50. Klapstein GJ, Colmers WF: Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J Neurophysiol, 1997, 78, 1651-1661.
51. Koh JY, Choi DW: Quantitative determination of glutamate-mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods, 1987, 83-90.
52. Kohler Ch, Eriksson L, Davies S, Chan-Palay V: Neuropeptide Y innervation of the hippocampal region in the rat and monkey brain. J Comp Neurol, 1986, 244, 384-400.
53. Kondratyev A, Gale K: Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kainic acid-evoked status epilepticus. Mol Brain Res, 2000, 75, 216-224.
54. Lea IV PM, Movsesyan VA, Faden Al: Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol, 2005, 145, 527-534.
55. Lea IV PM, Faden AI: Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev, 2006, 12, 149-166.
56. Lee JM, Zipfel GJ, Choi DW: The changing landscape of ischemic brain injury mechanisms. Nature, 1999, 399, A7-A14.
57. Liu W, Liu R, Chun JT, Bi R, Hoe W, Schreiber SS, Baudry M: Kainate excitotoxicity in organotypic hippocampal slice cultures: evidence for multiple apoptotic pathways. Brain Res, 2001, 916, 239-248.
58. Makarewicz D, Duszczyk M, Gadamski R, Danysz W, Lazarewicz JW: Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models. Neurochem Int, 2006, 48, 485-490.
59. Malva JO, Carvalho AP, Carvalho CM: Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem Int, 1998, 32, 1-6.
60. Meldrum BS: Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev, 1990, 2, 27-57.
61. Movsesyan VA, O'Leary DM, Fan L, Bao W, Mullins PGM, Knoblach SM, Faden AI: mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J Pharmacol Exp Ther, 2001, 296, 41-47.
62. Movsesyan VA, Stoica BA, Faden AI: MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem, 2004, 89, 1528-1536.
63. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke, 1995, 26, 503-513.
64. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y et al.: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature, 1995, 376, 37-43.
65. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci, 1996, 19, 267-71.
66. Nicoletti F, Bruno V, Catania MV, Battaglia G, Copani A, Barbagallo G, Cena V et al.: Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology, 1999, 38, 1477-1484.
67. Novellis V, Marabese I, Palazzo E, Rossi F, Berrino L, Rodella L, Bianchi R, Rossi F, Maione S: Group I metabotropic glutamate receptors modulate glutamate and gamma-aminobutyric acid release in the periaqueductal grey of rats. Eur J Pharmacol, 2003, 462, 73-81.
68. O'Leary DM, Movsesyan VA, Vicini S, Faden AI: Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol, 2000, 131, 1429-1437.
69. Olney JW: Neurotoxicity of excitatory amino acids. In: Kainic Acid as a Tool in Neurobiology. Ed. McGeer EG, Olney JW, McGeer PL, Raven Press, New York, 1978, pp. 95-121.
70. Olney JW, Ishimaru MJ: Excitotoxic cell death. In: Cell Death and Diseases of the Nervous System. Ed. Koliatsos VE, Ratan RR, Humana Press, Totowa NJ, 1999, 197-220.
71. Pin JP, Duvoisin R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995, 34, 1-26.
72. Pisani A, Calabresi P, Centonie D, Bernardi G: Enhancement of NMDA responses by group-I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol, 1997, 120, 1007-1014.
73. Pollard H, Charriaut-Marlangue C, Cantagrel S, Represa A, Robain O, Moreau J, Ben-Ari Y: Kainate-induced apoptotic cell death in hippocampal neurons. Neuroscience, 1994, 6, 7-18.
74. Popoli P, Pintor A, Tebano MT, Frank C, Pepponi R, Nazzicone V, Grieco R et al.: Neuroprotective effects of the mGluR5 antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J Neurochem, 2004, 89, 1479-1489.
75. 2+ entry. J Neurosci, 1997, 17, 8169-8177.
76. Rao AM, Hatcher JF, Dempsey RJ: Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci Lett, 2000, 293, 1-4.
77. + channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions. Neuroscience, 2006, 137, 211-220.
78. Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci, 1995, 18, 57-58.
79. Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature, 1998, 391, 96-99.
80. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ et al.: Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci, 1997, 17, 7503-7522.
81. Shih YH, Chein YC, Wang JY, Fu YS: Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. Neurosci Lett, 2004, 362, 136-140.
82. Shih YH, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS: Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. Neuroreport, 2002, 13, 515-519.
83. Silva AP, Carvalho AP, Carvalho CM, Malva JO: Modulation of intacellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J Neurochem, 2001, 79, 286-296.
84. Silva AP, Carvalho AP, Carvalho CM, Malva JO: Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology, 2003, 42, 282-292.
85. Silva AP, Pinheiro PS, Carvalho AP, Carvalho CM, Jakobsen B, Zimmer J, Malva JO: Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J, 2003, 17, 1118-1120.
86. Silva AP, Xapelli S, Pinheiro PS, Ferreira R, Lourenco J, Cristovao A, Grouzmann E: Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats. J Neurochem, 2005, 93, 163-170.
87. Silva AP, Xapelli S, Grouzmann E, Cavadas C: The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr Drug Targets CNS Neurol Disord, 2005, 4, 331-341.
88. Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT: Kainic acid induces apoptosis in neurons. Neuroscience, 1996, 75, 1047-1055.
89. Slassi A, Isaac M, Edwards L, Minidis A, Wensbo D, Mattsson J, Nilsson K et al.: Recent advances in noncompetitive mGluR5 receptor antagonists and their potential therapeutic applications. Curr Top Med Chem, 2005, 5, 897-911.
90. Smolders I, Lindekens H, Clinckers R, Meurs A, O'Neill MJ, Lodge D, Ebinger G, Michotte Y: In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands. J Neurochem, 2004, 88, 1068-1077.
91. Śmiałowska M, Bijak M, Sopala M, Tokarski K: Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Neuropeptides, 1996, 30, 7-12.
92. Śmiałowska M, Wierońska JM, Szewczyk B: Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol J Pharmacol, 2003, 55, 979-986.
93. Temple MD, O'Leary DM, Faden AI: The role of glutamate receptors in the pathophysiology of traumatic central nervous system injury. In: Head Trauma: Basic, Preclinical, and Clinical Directions. Ed. Miller LA, Hayes RL, Newcomb JK, John Wiley & Sons Inc., New York, 2001, 87-113.
94. Thomas LS, Jane DE, Harris JR, Croucher MJ: Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology, 2000, 39, 1554-1566.
95. Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W, Goldberg SR, Palmiter RD, Cadet JL: Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci, 2005, 25, 5273-5279.
96. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY: Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol, 2005, 31, 3-16.
97. Wahlgren NG, Ahmed N: Neuroprotection in cerebral ischemia: facts and fancies - the need for new approaches. Cerebrovasc Dis, 2004, 17, 153-166.
98. Woldbye DPD, Madsen TM, Larsen PJ, Mikkelsen JD, Bolwig TG: Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res, 1996, 737, 162-168.
99. Woldbye DPD, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG: Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med, 1997, 3, 761-764.
100. Wu Y, Li S: Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. Acta Pharmacol Sin, 2005, 26, 63-68.